Marathi | HIndi
The Drug Controller General of India (DCGI), on Saturday gave approval for the commercial launch of India's first Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) test, developed by the Tata Group and CSIR-IGIB (Institute of Genomics and Integrative Biology).
The Drugs Controller General of India (DCGI) has allowed Serum Institute of India (SII) to restart its phase two and three clinical trials for COVID-19 vaccine after the pharma major submitted the recommendations of the Data Safety Monitoring Board (DSMB), UK and DSMB India and requested permission to restart enrolment in the subject clinical trial of the vaccine being developed by AstraZeneca and Oxford University.
New Delhi, Sep 12 The Drug Controller General of India (DCGI) has directed the Serum Institute of India ...
The Drugs Controller General of India (DCGI) Dr VG Somani on Friday ordered the pharma giant Serum Institute of India (SII) to suspend any new recruitment in phase 2 and 3 clinical trials for COVID-19 vaccine till further orders.
The Drugs Regulator General of India (DCGI) has issued a show-cause notice to pharma giant Serum Institute of India (SII) asking for an explanation as to why the ongoing clinical trial of Covishield vaccine candidate has not been suspended till doubts about patient safety are cleared.
Dr Reddy's Laboratories on Wednesday announced the launch of Remdesivir under the brand name Redyx for Indian markets.
New Delhi, Aug 6 Glenmark Pharmaceuticals, a research-led global pharmaceutical company, on Thursday announced that it is set to ...
The Union Health and Family Welfare Ministry has directed the Drugs Controller General of India (DCGI) to ensure equitable distribution of drugs across the country included as part of "investigational therapies" in clinical management protocol for COVID-19.
Even as the Drugs Controller General of India (DCGI) has given permission to Itolizumab drug for restricted emergency use on moderate to severe COVID-19 patients, the Union Health Ministry has decided not to include the drug in the national treatment protocol for coronavirus patients.